DocDollars

Apellis Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000931823

Total reported 2019–2025
$55.1M
#160 of 2,960 reporting companies — 0.1% of all reported industry payments
$14.0M in general payments across 31,801 records, plus $41.2M in research funding across 6,261 records.

How it breaks down

General payments $13,970,628
Research funding $41,169,164

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Apellis Pharmaceuticals, Inc. reported $55.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #160 of 2,960 reporting companies. 75% of that was research funding and 25% general payments such as consulting, speaking, food and travel. 31,801 general payment records and 6,261 research records were filed.

Common questions about Apellis Pharmaceuticals, Inc.

How much has Apellis Pharmaceuticals, Inc. paid US doctors?

Apellis Pharmaceuticals, Inc. reported $55,139,791 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $13,970,628 in general payments, $41,169,164 in research funding.

How does Apellis Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #160 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Apellis Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.